Contents

Diagnostic efficacy of some plasma parameters in stable
Coronary heart disease and acute coronary syndrome
T. Kvantaliani, P. Tsiklauri, N. Barnabishvili
Acad. M. Tsinamdzgvrishvili Institute of Cardiology,
Scientific-Research Laboratory "Test-Physician's House"

Key words: Acute coronary syndrome, C-reactive protein, Chlamydia pneumoniae infection.

 The goal of the performed study was to evaluate the diagnostic value of acute phase proteins - C-reactive protein (CRP) and fibrinogen (F), as well as blood fibrinolytic activity (BFA), lipoprotein profile and TC/HDL ratio, reflecting atherogenicity of lipoprotein spectrum along with CK-MB - direct biochemical marker of myocardial damage in different clinical presentations of CHD, namely in patients with stable CHD (I group) and acute coronary syndrome-ACS (II group), seropositive to Chlamydia pneumoniae (Chl.pn.) infection. 52 patients - 34 men (mean age 58,8±0,2) and 18 women (mean age 61,2±1,8) and 18 normal (III group) persons (mean age 59,2±2,1) were examined.

The intergroup analysis of investigated parameters revealed statistically significant difference between I and II groups, namely elevated plasma concentrations of Chl .pn. specific IgA and IgA+IgG antibody titers, as well as the expected increase in CRP and CK-MB but considerable decrease of BFA in patients with ACS (II group) on the background of almost similarly disturbed lipoprotein metabolism. According to our study assessment of IgA+IgG antibodies and their serum concentrations together with other biochemical markers of inflammatory activity in patients with unstable angina, especially in cases of slight , moderate or without any elevation of markers of myocardial damage or disability of their measurement, may provide additional insights in the diagnosis of ACS.

Reference:

1.        Насонов Е.Л., Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кардиология, 1999, 2: 81-85.

2.        Шатилина Л.В., Уразгильдеева С.А., Мнускина М.М., Оганесян Л.В., Макарова И.Н., Гуревич В.С., Антифосфолипидная активность крови у больных ИБС с тромбогенными осложнениями. Клин. Мед. 2003, 12: 30-32.

3.        3.Akhvlediani N.V., Emukhvari M.G., Sharabidze N.A., Diagnostic value of determination of C-reactive protein and different class lipids in patients with hypercholesterolemia. Georgian Med. News, 2002, 7-8: 45-47.

4.        Ballantyne Ch.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., Sharrett R. Lipoprotein - associated phospholipase A2, high-sensitivity C-reactive protein and risk for incidental coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study, circulation 2004, 24: 837-842.

5.        Berk B.C., Weintraub W.S., Alexander R.W. Elevation of C-reactive protein in "acute" coronary artery syndrome. Am.J.Cardiol. 1990, 65: 168-172.

6.        Bertrand M.E. Chair, Simoons M.L., Fox K.A.A., Wallentin L.C., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart Journal 2002, 23; 1809-1840.

7.        Biasucci L.M., LiuzzoG., Angiolilo D.G.,Masseri A. Inflammation and acute

8.        coronary syndromes. Herz, 2000; 108-12.

9.        Cook P.J., Lip G.Y. Infectious agents and atherosclerotic vascular disease. Q.J.Med., 1996, 89: 727-735.

10.     Ishii J., Wang J., Naruse H., et al. Serum concentration of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clinical Chemistry 1997, 43,8; 1372-1378.

11.     Jackson L.A., Campbell L.A., Schmidt R.A., Kvo C.C., Cappuccio A.L., Lee M.J., Grayston J.T. Specificity of detection of Chlamydia Pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am J Pathol., 1997, 150: 1785-1790.

12.     Linnanmaki E., Leinonen M., Mattila K. et al. Chlamydia pneumoniae- specific circulating immune complexes in patients with chronic coronary heart disease. Circulation, 1993, V.87, p.1130-1134.

13.     Mash F., Lovis C., Gaspoz J.M., et al. C-reactive protein as a marker for acute coronary syndrome. Eur. Heart J., 1997, 18: 1897-1902.

14.     Mehta J.L., Saldeen T.G.P., Rand K. Interactive role of infection inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J.Am. Coll.Cardiol., 1998, 31: 1217-1225.

15.     Morrow D.A., Antman E.M., Rifai N. et al. C-reactive protein and rapid bed-side troponon-T independently predict mortality in acute coronary syndrome: a TIMI IIIA Substudy. Circulation, 1997, 96, Suppl. 1: 1-216

16.     Rifai N., Ridker P.M. A proposed cardiovascular risk assessment algorithm employing high-sensitivity C-reactive protein and lipid screening. Clin. Chem., 2001, 47: 28-30.

17.     Saikku P. Diagnosis of acute and chronic Chlamydia pneumoniae infection. Proc. Eigth. Int. Symp. on Human Chlamydial Infection., Chantilly, 1994, 163-172.

18.     Saikku P., Leinonen M., Mattila K. et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet, 1988, ii: 983-985.

19.     Shor A., Kuo C.C., Patton D.L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. South African Med. J., 1992, V.82,p.158-160.

20.     Taylor-Robinson D., Chlamydia pneumoniae in vascular tissue. Atherosclerosis, 1998, 140 (Suppl I): S 21-S 24.

21.     Toss H., Lindhal B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation, 1997, 96: 4204-4210.

Contents